BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24689343)

  • 1. Commentary: tenofovir is superior to entecavir in HBeAg-positive chronic hepatitis B patients.
    Bradshaw D; Danta M
    Aliment Pharmacol Ther; 2014 May; 39(9):992. PubMed ID: 24689343
    [No Abstract]   [Full Text] [Related]  

  • 2. Commentary: tenofovir is superior to entecavir in HBeAg-positive chronic hepatitis B patients--authors' reply.
    Gao L; Trinh HN; Li J; Nguyen MH
    Aliment Pharmacol Ther; 2014 May; 39(9):993. PubMed ID: 24689344
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter: Treatment of HBeAg+ chronic hepatitis B--is tenofovir truly superior to entecavir?
    Sadler MD; Lee SS
    Aliment Pharmacol Ther; 2014 Jun; 39(11):1339. PubMed ID: 24803253
    [No Abstract]   [Full Text] [Related]  

  • 4. Letter: Treatment of HBeAg+ chronic hepatitis B--is tenofovir truly superior to entecavir? Authors' reply.
    Gao L; Trinh HN; Li J; Nguyen MH
    Aliment Pharmacol Ther; 2014 Jun; 39(11):1339-40. PubMed ID: 24803254
    [No Abstract]   [Full Text] [Related]  

  • 5. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.
    Woo G; Tomlinson G; Nishikawa Y; Kowgier M; Sherman M; Wong DK; Pham B; Ungar WJ; Einarson TR; Heathcote EJ; Krahn M
    Gastroenterology; 2010 Oct; 139(4):1218-29. PubMed ID: 20600036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letter: First-line monotherapies for chronic hepatitis B - indirect comparison between entecavir and tenofovir.
    Maratea D; Fadda V; Trippoli S; Messori A
    Aliment Pharmacol Ther; 2013 Mar; 37(5):584-5. PubMed ID: 23369168
    [No Abstract]   [Full Text] [Related]  

  • 7. [Efficacy and treatment strategy for drug resistances of nucleos(t)ide analogues for chronic hepatitis B].
    Hosaka T; Suzuki F; Kumada H
    Nihon Shokakibyo Gakkai Zasshi; 2011 Feb; 108(2):210-4. PubMed ID: 21307624
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparison of the efficacy of entecavir and tenofovir in chronic hepatitis B.
    Güzelbulut F; Ovünç AO; Oetinkaya ZA; Senates E; Gökden Y; Saltürk AG; Sezikli M; Ozkara S; Cetinkaya F
    Hepatogastroenterology; 2012; 59(114):477-80. PubMed ID: 21940383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
    Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
    Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Protocol for the antiviral therapy of chronic hepatitis B].
    ;
    Orv Hetil; 2008 Dec; 149(49):2341-3. PubMed ID: 19042187
    [No Abstract]   [Full Text] [Related]  

  • 11. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
    Park JG; Park SY
    Clin Mol Hepatol; 2015 Sep; 21(3):242-8. PubMed ID: 26523269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Improvement of health-related quality of life in chronic hepatitis B patients treated with entecavir or adefovir].
    Yu JH; Li Q; Yang X; Fan WB; Xie SS; Li WW; Liu L; Chen SJ
    Zhonghua Gan Zang Bing Za Zhi; 2011 Apr; 19(4):305-6. PubMed ID: 21805739
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir.
    Ridruejo E
    World J Gastroenterol; 2014 Jun; 20(23):7169-80. PubMed ID: 24966587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?
    Vlachogiannakos J; Papatheodoridis GV
    Liver Int; 2015 Jan; 35 Suppl 1():100-6. PubMed ID: 25529094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New perspectives in the therapy of chronic hepatitis B.
    Lampertico P; Liaw YF
    Gut; 2012 May; 61 Suppl 1():i18-24. PubMed ID: 22504916
    [No Abstract]   [Full Text] [Related]  

  • 16. Incorporated antivirals for chronic hepatitis B in Brazil: a cost-effectiveness analysis.
    Oliveira GL; Almeida AM; Silva AL; Brandão CM; Andrade EI; Cherchiglia ML; Acurcio Fde A
    Rev Saude Publica; 2013 Aug; 47(4):769-78; discussion 779. PubMed ID: 24346678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canadian patients with chronic hepatitis B cannot access appropriate drug treatments: a call for change.
    Sherman M; Lee SS
    Can J Gastroenterol; 2011 Oct; 25(10):538-41. PubMed ID: 22059156
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimal therapy of chronic hepatitis B: how do I treat my HBeAg-negative patients?
    Viganò M; Invernizzi F; Lampertico P
    Liver Int; 2015 Jan; 35 Suppl 1():107-13. PubMed ID: 25529095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
    Dakin H; Fidler C; Harper C
    Value Health; 2010 Dec; 13(8):934-45. PubMed ID: 20825624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of efficacy between adefovir dipivoxil and entecavir in patients with chronic hepatitis B].
    Yang F; Wu XF; Wei N
    Zhonghua Gan Zang Bing Za Zhi; 2010 Jan; 18(1):65-6. PubMed ID: 20128975
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.